Linopristin/flopristin

Drug Profile

Linopristin/flopristin

Alternative Names: NXL-103; RPR 202868/RPR 132552; XRP 2868

Latest Information Update: 06 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer AstraZeneca
  • Class Antibacterials; Streptogramins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Community-acquired pneumonia; Skin and soft tissue infections

Most Recent Events

  • 03 Sep 2015 No recent reports on development identified - Phase-II for Community-acquired pneumonia in Ukraine, Romania, Poland, Estonia, Peru, Croatia, Germany, South Africa and Chile (PO)
  • 03 Sep 2015 No recent reports on development identified - Phase-II for Skin and soft tissue infections in Guatemala and USA (PO)
  • 06 Nov 2009 Phase-II clinical trials in Skin and soft tissue infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top